The federal Project Grant award of $136,661 provided by the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) supports the development of an innovative high-throughput reporter assay called PADIT-SEQ. This technology will be used to uncover fundamental principles governing transcription factor (TF) binding affinity and specificity to DNA sequences, with the goal of advancing the mechanistic understanding of gene regulation and how noncoding genetic variants contribute to human disease. Key research objectives include determining the role of auxiliary DNA binding sites and shape features in TF genomic occupancy, identifying TFs affected by disease-associated noncoding variants, and elucidating intrinsic orientation biases of DNA binding domains. The award recipient is Brigham & Women's Hospital Inc., a leading academic medical center and research institution in Boston, Massachusetts, which is a subsidiary of the parent organization Partners Healthcare System Incorporated. The research is expected to be completed by August 31, 2026.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $136.7k | 9/23/24 |